Medigene AG reports Financial Results and Business Update for Q3 2024
October 24, 2024 01:30 ET
|
Medigene AG
Planegg/Martinsried, October 24, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Immunocore to present at the 2024 Cantor Global Healthcare Conference
September 12, 2024 16:05 ET
|
Immunocore Holdings plc
Immunocore to present at the 2024 Cantor Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 12 September 2024) Immunocore Holdings plc (Nasdaq:...
Medigene Reports Results of Annual General Meeting
June 24, 2024 11:05 ET
|
Medigene AG
Shareholders approve all proposed resolutionsRe-election of two members of the Supervisory BoardReduction of share capital by consolidation of shares at a ratio of 2:1 approvedCreation of new...
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
June 18, 2024 07:00 ET
|
Immunocore Holdings plc
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma ...
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
June 01, 2024 08:00 ET
|
Immunocore Holdings plc
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were...
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
May 31, 2024 16:05 ET
|
Immunocore Holdings plc
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 Monotherapy...
Immunocore to present at the Jefferies Global Healthcare Conference
May 30, 2024 16:00 ET
|
Immunocore Holdings plc
Immunocore to present at the Jefferies Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 30 May 2024) Immunocore Holdings plc (Nasdaq: IMCR)...
TCR UK and Woya Digital Renew Marketing Partnership for 2024
May 10, 2024 12:32 ET
|
TCR UK
Birmingham, UK, May 10, 2024 (GLOBE NEWSWIRE) -- TCR UK and Woya Digital Renew Marketing Partnership for 2024 TCR UK is thrilled to announce the renewal of its marketing partnership with Woya...
Immunocore reports first quarter financial results and provides a business update
May 08, 2024 07:00 ET
|
Immunocore Holdings plc
Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7...
Sport77 and J.A.S Motorsport Announces New UK Motorsport Partnership
March 08, 2024 10:02 ET
|
Sport77 Ltd
London, UK, March 08, 2024 (GLOBE NEWSWIRE) -- Sport77 and J.A.S Motorsport are pleased to announce a new association that will increase support and access to Honda racing products in the United...